Community Hospital Purchases BVA Analyzer With Focus on Improving Outpatient Heart Failure Care Oak Ridge, TN, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology through the acquisition of the BVA analyzer. This advancement not only enhances revenue streams, but also sets the stage for projected accelerated sales growth for the rest of the year. A rural 339-bed comm ...

Oak Ridge, TN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it has been awarded a $1.9M two-year contract from the U.S. Air Force (USAF) to support the continued development of a novel fluorescent tracer and optical sensing technology into a next-generation point-of-care blood volume analyzer for military and civilian applications. Michael Feldschuh, Daxor's President and CEO, highlighted the significance of this ...

Core Insights - Daxor Corporation is expanding its blood volume analysis (BVA) services with the launch of the ezBVA lab service in three new facilities, anticipating sustained accelerated sales growth for the remainder of the year [1][3] Company Developments - Recent sales achievements include the adoption of Daxor's ezBVA Lab service by a leading full-service medical center in Georgia, a purchase by a hospital in North Carolina that is part of the largest non-profit health system, and implementation by a top-rated hospital in Central Florida [2] - The ezBVA lab service is a CLIA certified facility that provides next-day blood volume analysis results, enhancing patient care while managing healthcare expenses [3] Technology and Impact - Daxor's BVA-100® is the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition, with over 65,000 tests performed across leading U.S. hospital centers [4] - The technology has shown significant benefits in reducing mortality and readmissions in heart failure and critical care patients, indicating its critical role in fluid management [4]

The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA) Oak Ridge, TN, July 24, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that Daxor has received a $550K matchingfund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This additional funding will support adding hematocrit measurement to a future generation blood volume analyzer. The upgrade eliminate ...

Daxor's ezBVA Lab Service Emerges as Key Driver for Expansion and Market Penetration Recent sales wins include: "Our unwavering focus on expanding market presence continues to yield strong results. The strategic investments we've made in our sales and marketing efforts are clearly bearing fruit," stated Michael Feldschuh, CEO and President of Daxor. "This growth underscores the increasing recognition of our blood volume analysis technology as a critical tool in improving patient outcomes." Daxor Corporation ...

Core Insights - Daxor Corporation is a leader in blood volume measurement technology, showcasing its innovative BVA technology at the AAHFN Annual Meeting, emphasizing its potential to improve heart failure management and overall cardiovascular care [1][2] - The BVA-100® is the only FDA-cleared diagnostic blood test for accurate blood volume status and composition, with over 65,000 tests performed, significantly reducing mortality and readmissions in heart failure and critical care [1] - Daxor is engaged in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [1] Event Participation - Daxor Corporation will exhibit at the AAHFN 20th Annual Meeting from June 20-22, 2024, in Orlando, Florida, aimed at advancing nursing education and improving heart failure patient outcomes [2]

Core Insights - Daxor Corporation will exhibit at the AAHFN 20th Annual Meeting from June 20-22, 2024, showcasing its blood volume measurement technology [1][4] - The AAHFN is focused on improving heart failure patient outcomes through education, clinical practice, and research [1] - Daxor's BVA technology is positioned as a transformative tool in heart failure management, aiming to reduce hospital stays, 30-day readmissions, and mortality rates [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, known for its BVA-100® diagnostic test, which is FDA-cleared for accurate blood volume quantification [8] - Over 65,000 tests have been conducted in U.S. hospitals, contributing to improved performance metrics in various medical conditions, particularly in heart failure and critical care [8] - The company is engaged in ongoing trials for heart failure treatment with NIH support and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [8]

Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients. Data from both studies demonstrated a lack of ...

The Premier Event for Cardiovascular Industry Leaders and Clinicians Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring'24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024. The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought leaders from acro ...

450-Bed Hospital Purchases BVA-100™ Blood Volume Analyzer to Launch Heart Failure Program Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the purchase of Daxor's BVA-100™ at a 450-bed teaching hospital in the greater Chicago area. "Hospitals are utilizing our BVA diagnostic to save money by reducing length of stay while improving Hospital Readmissions Reduction Program (HRRP) quality metrics such as 30 ...